159 related articles for article (PubMed ID: 37094904)
1. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
2. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
3. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
4. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma.
Guan J; Li M; Wang Y; Zhang Y; Que Y; Lu S; Wang J; Zhu J; Huang J; Zhen Z; Sun F; Song M; Zhang Y
Cell Death Dis; 2024 Feb; 15(2):124. PubMed ID: 38336749
[TBL] [Abstract][Full Text] [Related]
5. SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma.
Hua Z; Chen B; Gong B; Lin M; Ma Y; Li Z
CNS Neurosci Ther; 2024 Mar; 30(3):e14664. PubMed ID: 38516781
[TBL] [Abstract][Full Text] [Related]
6. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.
Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X
J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985
[TBL] [Abstract][Full Text] [Related]
7. Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression.
Chittavanich P; Saengwimol D; Roytrakul S; Rojanaporn D; Chaitankar V; Srimongkol A; Anurathapan U; Hongeng S; Kaewkhaw R
Mol Oncol; 2024 Apr; 18(4):918-938. PubMed ID: 37975412
[TBL] [Abstract][Full Text] [Related]
8. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
[TBL] [Abstract][Full Text] [Related]
9. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus.
McGuire TR; Coulter DW; Bai D; Sughroue JA; Li J; Yang Z; Qiao Z; Liu Y; Murry DJ; Chhonker YS; McIntyre EM; Alexander G; Sharp JG; Li R
BMC Cancer; 2019 Aug; 19(1):837. PubMed ID: 31455317
[TBL] [Abstract][Full Text] [Related]
11. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY
Mol Oncol; 2021 Apr; 15(4):1162-1179. PubMed ID: 33497018
[TBL] [Abstract][Full Text] [Related]
12. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma.
Lu Y; Yang Q; Su Y; Ji Y; Li G; Yang X; Xu L; Lu Z; Dong J; Wu Y; Bei JX; Pan C; Gu X; Li B
Cell Death Dis; 2021 May; 12(6):511. PubMed ID: 34011924
[TBL] [Abstract][Full Text] [Related]
13. Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation.
Jiang P; Zhang T; Wu B; Li X; Fu M; Xu B
Med Oncol; 2023 Oct; 40(11):332. PubMed ID: 37843625
[TBL] [Abstract][Full Text] [Related]
14. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L; Mohammad MA; Milazzo G; Moreno-Smith M; Patel TD; Zorman B; Badachhape A; Hernandez BE; Wolf AB; Zeng Z; Foster JH; Aloisi S; Sumazin P; Zu Y; Hicks J; Ghaghada KB; Putluri N; Perini G; Coarfa C; Barbieri E
Nat Commun; 2022 Jun; 13(1):3728. PubMed ID: 35764645
[TBL] [Abstract][Full Text] [Related]
15. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
16. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
Stermann A; Huebener N; Seidel D; Fest S; Eschenburg G; Stauder M; Schramm A; Eggert A; Lode HN
Cancer Immunol Immunother; 2015 Oct; 64(10):1215-27. PubMed ID: 26076666
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Dysregulation in
Epp S; Chuah SM; Halasz M
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069407
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance.
Jain D; Somasundaram DB; Aravindan S; Yu Z; Baker A; Esmaeili A; Aravindan N
Cell Biol Toxicol; 2023 Jun; 39(3):967-989. PubMed ID: 34773529
[TBL] [Abstract][Full Text] [Related]
19. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Yu Y; Ding J; Zhu S; Alptekin A; Dong Z; Yan C; Zha Y; Ding HF
Cell Death Dis; 2021 Aug; 12(9):821. PubMed ID: 34462431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
